Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

NCT04210115 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

703

Enrollment

INDUSTRY

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma (ESCC)
Gastroesophageal Junction Carcinoma (GEJC)
Esophageal Adenocarcinoma (EAC)

Interventions

BIOLOGICAL: pembrolizumab
DRUG: placebo
DRUG: cisplatin
DRUG: 5-FU
RADIATION: radiotherapy
DRUG: leucovorin
DRUG: levoleucovorin
DRUG: oxaliplatin

Sponsor

Merck Sharp & Dohme LLC